We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Read MoreHide Full Article
Key Takeaways
Precigen is seeking growth beyond Papzimeos through its AdenoVerse platform and clinical pipeline.
Precigen's PRGN-2009 is being studied with Keytruda in recurrent or metastatic cervical cancer.
Papzimeos generated $74.6 million in first-half 2026 revenues, more than doubling sequentially in Q2.
Precigen (PGEN - Free Report) is focused on building long-term growth visibility beyond its commercial-stage Papzimeos franchise through its AdenoVerse platform. While Papzimeos is currently driving the company’s revenue growth, the platform’s clinical progress could provide additional opportunities across multiple indications.
The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy, in HPV-driven cancers.
The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform. Management noted that the designation could benefit PRGN-2009 across multiple HPV-associated cancers, including cervical and oropharyngeal cancers, as well as future candidates targeting other cancers and diseases.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026. Management believes the success of Papzimeos and progress with PRGN-2009 reflect the platform's utility and support its long-term potential.
Though still in the early stages, it remains to be seen whether the potential expansion of the AdenoVerse platform could eventually complement Papzimeos and provide long-term growth visibility.
PGEN Banks on Papzimeos Commercial Uptake
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base.
Papzimeos has witnessed strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos more than doubled sequentially during the second quarter of 2026.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
A potential approval in Europe could further boost the drug’s sales and drive revenues.
Papzimeos also benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application for INO-3107 is currently under review in the United States, with a decision from the FDA expected on Oct. 30, 2026. INO remains focused on advancing the INO-3107 program toward a potential 2026 approval and commercialization.
PGEN’s Price Performance, Valuation and Estimates
Year to date, shares of Precigen have rallied 78% compared with the industry’s rise of 9.6%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Precigen is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 60.87 times trailing 12-month book value, higher than 4.02 times for the industry. The stock is also trading above its five-year mean of 4.28.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 bottom line has improved from a loss of 2 cents per share to earnings of 25 cents over the past 60 days. During the same time, earnings estimates for 2027 have increased from 25 cents per share to 86 cents during the same time.
View the Zacks #1 Rank List
Image: Bigstock
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Key Takeaways
Precigen (PGEN - Free Report) is focused on building long-term growth visibility beyond its commercial-stage Papzimeos franchise through its AdenoVerse platform. While Papzimeos is currently driving the company’s revenue growth, the platform’s clinical progress could provide additional opportunities across multiple indications.
The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy, in HPV-driven cancers.
The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform. Management noted that the designation could benefit PRGN-2009 across multiple HPV-associated cancers, including cervical and oropharyngeal cancers, as well as future candidates targeting other cancers and diseases.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026. Management believes the success of Papzimeos and progress with PRGN-2009 reflect the platform's utility and support its long-term potential.
Though still in the early stages, it remains to be seen whether the potential expansion of the AdenoVerse platform could eventually complement Papzimeos and provide long-term growth visibility.
PGEN Banks on Papzimeos Commercial Uptake
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base.
Papzimeos has witnessed strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos more than doubled sequentially during the second quarter of 2026.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
A potential approval in Europe could further boost the drug’s sales and drive revenues.
Papzimeos also benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application for INO-3107 is currently under review in the United States, with a decision from the FDA expected on Oct. 30, 2026. INO remains focused on advancing the INO-3107 program toward a potential 2026 approval and commercialization.
PGEN’s Price Performance, Valuation and Estimates
Year to date, shares of Precigen have rallied 78% compared with the industry’s rise of 9.6%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Precigen is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 60.87 times trailing 12-month book value, higher than 4.02 times for the industry. The stock is also trading above its five-year mean of 4.28.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 bottom line has improved from a loss of 2 cents per share to earnings of 25 cents over the past 60 days. During the same time, earnings estimates for 2027 have increased from 25 cents per share to 86 cents during the same time.
Image Source: Zacks Investment Research
PGEN’s Zacks Rank
Precigen currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.